Baxter Stops Medication Management R&D Efforts To Focus On FDA Seizure
This article was originally published in The Gray Sheet
Executive Summary
Baxter will halt all product development in its medication management division while it addresses design flaws with Colleague infusion pumps, seized by FDA Oct. 13
You may also be interested in...
Malfunctions Prompt Baxter Withdrawal Of Ambulatory Infusion Pump
Baxter Healthcare will withdraw its only ambulatory infusion pump from the market over the next year and take a $45 mil. charge in the fourth quarter following several reports of device malfunction
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”